This paper is in the following e-collection/theme issue:

COVID-19 Vaccination (126) JMIR Theme Issue: COVID-19 Special Issue (2388) Infectious Diseases (non-STD/STI) (1478) Vaccination and Immunization in the Digital Age (343) Outbreak and Pandemic Preparedness and Management (1673) Prevention and Health Promotion (879) Hygiene and Infection Prevention (297) Theme Issue: Novel Coronavirus (COVID-19) Outbreak Rapid Reports (1481)

Published on in Vol 8, No 5 (2022): May

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/35311, first published .
Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis

Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis

Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis

Authors of this article:

Cong Liu1 Author Orcid Image ;   Junghwan Lee1 Author Orcid Image ;   Casey Ta1 Author Orcid Image ;   Ali Soroush1 Author Orcid Image ;   James R Rogers1 Author Orcid Image ;   Jae Hyun Kim2 Author Orcid Image ;   Karthik Natarajan1 Author Orcid Image ;   Jason Zucker3 Author Orcid Image ;   Yehoshua Perl4 Author Orcid Image ;   Chunhua Weng1 Author Orcid Image
Article Authors Cited by (14) Tweetations (3) Metrics

Journals

  1. Vivaldi G, Jolliffe D, Holt H, Tydeman F, Talaei M, Davies G, Lyons R, Griffiths C, Kee F, Sheikh A, Shaheen S, Martineau A. Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK). The Lancet Regional Health - Europe 2022;22:100501 View
  2. Kandeel A, Fahim M, Deghedy O, Alim W, Fattah M, Afifi S, Mohsen A, Abdelghaffar K. Clinical features and severe outcome predictors of COVID-19 vaccine breakthrough infection among hospitalized patients: results from Egypt severe acute respiratory infections sentinel surveillance, 2021–2022. BMC Infectious Diseases 2023;23(1) View
  3. Gomaa A, Abdel-Wadood Y, Gomaa M. Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild–moderate COVID-19 and prevention of post-COVID cognitive impairment. Inflammopharmacology 2022;30(6):1977 View
  4. Karahan M, Kervan U, Kocabeyoglu S, Sert D, Tekce Y, Yavuz O, Kucuker S, Ozatik M, Catav Z, Sener E. CoronaVac, BNT162b2 and heterologous COVID-19 vaccine outcomes in patients with ventricular assist device. The International Journal of Artificial Organs 2023;46(1):15 View
  5. Tan K, Ang A, Tay D, Somani J, Ng A, Peng L, Chu J, Tambyah P, Allen D. Detection of hospital environmental contamination during SARS-CoV-2 Omicron predominance using a highly sensitive air sampling device. Frontiers in Public Health 2023;10 View
  6. Kshirsagar M, Nasir M, Mukherjee S, Becker N, Dodhia R, Weeks W, Ferres J, Richardson B. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data. JMIR Public Health and Surveillance 2022;8(11):e38898 View
  7. Montoya A, Wen K, Travers J, Rivera-Hernandez M, White E, Mor V, Berry S. Resident Factors Associated With Breakthrough SARS-CoV-2 Infections. Journal of the American Medical Directors Association 2023;24(6):901 View
  8. DeSantis S, Yaseen A, Hao T, León-Novelo L, Talebi Y, Valerio-Shewmaker M, Pinzon Gomez C, Messiah S, Kohl H, Kelder S, Ross J, Padilla L, Silberman M, Tuzo S, Lakey D, Shuford J, Pont S, Boerwinkle E, Swartz M. Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants. The Journal of Infectious Diseases 2023;227(10):1164 View
  9. Teran R, Gagner A, Gretsch S, Lauritsen J, Galanto D, Walblay K, Ruestow P, Korban C, Pacilli M, Kern D, Black S, Tabidze I. SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020–2022. Emerging Infectious Diseases 2023;29(11) View
  10. Walmsley S, Nabipoor M, Lovblom L, Ravindran R, Colwill K, McGeer A, Dayam R, Manase D, Gingras A. Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination. Vaccines 2023;12(1):36 View
  11. Alshanqeeti S, Szpunar S, Anne P, Saravolatz L, Bhargava A. Epidemiology, clinical features and outcomes of hospitalized patients with COVID-19 by vaccination status: a multicenter historical cohort study. Virology Journal 2024;21(1) View
  12. Gillot C, Tré-Hardy M, Cupaiolo R, Blairon L, Wilmet A, Beukinga I, Dogné J, Douxfils J, Favresse J. Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273.. Virology 2024;595:110082 View
  13. Bytyci J, Ying Y, Lee L. Immunocompromised individuals are at increased risk of COVID‐19 breakthrough infection, hospitalization, and death in the post‐vaccination era: A systematic review. Immunity, Inflammation and Disease 2024;12(4) View
  14. Mateo-Urdiales A, Fabiani M, Mayer F, Sacco C, Belleudi V, Da Cas R, Fotakis E, De Angelis L, Cutillo M, Petrone D, Morciano C, Cannone A, Del Manso M, Riccardo F, Bella A, Menniti-Ippolito F, Pezzotti P, Spila Alegiani S, Massari M. Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021. BMC Public Health 2024;24(1) View